Nitya Nair

8PUBLICATIONS
48CO-AUTHORS
Molecular targetsAllergyGene and molecular therapyPredictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 03, 2026
Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

|Sep 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Georgina V Long, Nitya Nair, Daniel Marbach

|Oct 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.

Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper

|Oct 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.

Funda Meric-Bernstam, Randy F Sweis, F Stephen Hodi

|Mar 06, 2020
Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer.

Nitya Nair, Shih-Yu Chen, Ed Lemmens

|Jul 03, 2019
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Raffit Hassan, Evan Alley, Hedy Kindler

Pageof 2

Frequent Collaborators

2 joint publications

Daniel Marbach

2 joint publications

Georgina V Long

2 joint publications

Jason J Luke

2 joint publications

Amanda Enstrom